Tabrecta/ Rybrevant are expected to enter the market

Research on Tagrisso and Leclaza, respectively, and focus on resolving resistance

Two types of anticancer drugs targeting MET gene mutations are expected to enter the domestic market

Two types of anticancer drugs targeting MET gene mutations are expected to enter the domestic market.

 

According to related industries, Novartis Korea and Janssen Korea submitted applications to the MFDS for approval of the new anticancer drugs Tabrecta (Capmatinib) and Rybrevant (Amivantamab), respectively, and are currently undergoing screening.

 

MET mutations are rare types that account for about 3% to 4% of metastatic non-small cell lung cancer, and interest in these new drugs is increasing as there have been no treatments.

 

The two drugs have something in common that they target hepatocellular growth factor receptors (c-Met), but the indications are somewhat different.

 

Tabrecta was first approved in the United States in May last year as a treatment for MET Exon14 mutated non-small cell lung cancer (NSCLC).

 

In the case of Rybrevant, it obtained US approval in May, blocking epithelial cell growth factor (EGFR) and MET mutation at the same time.

 

The first indication of this drug is non-small cell lung cancer with EGFR Exon20 mutation.

 

Tabrecta and Rybrevant are spurring research for future combination therapy.

 

In particular, it is expected to be able to solve the resistance problem of EGFR TKI in lung cancer.

 

In fact, Tabrecta is conducting a clinical trial in combination with AstraZeneca's third-generation EGFR TKI Tabrecta (Osimertinib), while Rybrevant is conducting a study in combination with Yuhan's 'Leclaza(Lazertinib), a domestic new drug.

 

Meanwhile, Tabrecta confirmed its validity through a phase 2 GEOMETRY mono-1 study of 97 patients with METex14.

 

As a result of the study, the overall response rate was 68% in patients who had never been treated and 41% in patients who had previously been treated.

 

Among the patients who took Tabrecta, DoR of previously untreated patients was 12.6 months and the patients treated were 9.7 months.

 

Leclaza proved its efficacy through CHRYSALIS, a phase 1 clinical trial.

 

According to the study, the objective response rate (ORR) was 40% when 81 patients with non-small cell lung cancer with 20 mutations of EGFR Exon were administered with Rybrevant.

 

There were three patients with complete response (CR) with complete tumor disappearance, and 29 patients reached partial response (PR) with tumor size decreasing by more than 30%.